Ardelyx prepares to launch second late-stage study of hyperphosphatemia med tenapanor, development of hyperkalemia candidate RDX7675 terminated; shares up 7% premarket
Seeking Alpha,
Ardelyx (NASDAQ:ARDX) is up 7% premarket on modest volume on the heels of its announcement that enrollment will begin shortly…